Showing 19,581 - 19,600 results of 32,569 for search '(( 50 ((a decrease) OR (mean decrease)) ) OR ( e ((nn decrease) OR (point decrease)) ))', query time: 1.04s Refine Results
  1. 19581

    S9 Fig - by Alexander Bryson (11570876)

    Published 2021
    “…Reducing the membrane time constant of the Izhikevich model by reducing membrane capacitance increases the sensitivity of the model to correlated input. For instance, the mean spike threshold at 25% capacitance decreased from 19.6 to 3.3Hz for inputs with a pairwise cross-correlation of 0.005, compared to 4.9 to 3.3Hz at 100% capacitance. …”
  2. 19582

    Supplementary Material for: Anatomical, functional, and prognostic results of vitrectomy in epiretinal membranes secondary to retinal vein occlusions by Chung Y.-R. (20312844)

    Published 2024
    “…Anatomically, the mean preoperative CMT was 501 ± 168 μm, decreasing to 348 ± 108 μm at month 24 (p=0.008). …”
  3. 19583

    DataSheet1_Effects of pharmacogenomics-guided treatment on medication adherence and the antidepressant switching rate in major depressive disorder.docx by Chaoli Chen (20359785)

    Published 2024
    “…Background<p>In the treatment of depression, medication plays a crucial role. However, insufficient patient adherence to medication often results in unsatisfactory treatment outcomes, increasing both the recurrence and rehospitalization rates of depression, and consequently imposing a greater economic burden on the healthcare system.…”
  4. 19584
  5. 19585
  6. 19586
  7. 19587
  8. 19588
  9. 19589
  10. 19590
  11. 19591
  12. 19592
  13. 19593
  14. 19594
  15. 19595

    Data_Sheet_1_SWL-1 Reverses Fluconazole Resistance in Candida albicans by Regulating the Glycolytic Pathway.doc by Xiao-Ning Li (2008540)

    Published 2020
    “…In this study, we show that SWL-1 reverses resistance to fluconazole in C. albicans when delivered in combination, with a sharp decrease in the IC<sub>50</sub> of fluconazole from >200 to 3.74 ± 0.25 μg/ml, and also reverses the fluconazole resistance of C. albicans in vitro, with IC<sub>50</sub> from >200 to 5.3 ± 0.3 μg/ml. …”
  16. 19596

    An Integrated Disease/Pharmacokinetic/Pharmacodynamic Model Suggests Improved Interleukin-21 Regimens Validated Prospectively for Mouse Solid Cancers by Moran Elishmereni (203218)

    Published 2011
    “…Simulations of the verified model surfaced important therapeutic insights: (1) Fractionating the standard daily regimen (50 µg/dose) into a twice daily schedule (25 µg/dose) is advantageous, yielding a significantly lower tumor mass (45% decrease); (2) A low-dose (12 µg/day) regimen exerts a response similar to that obtained under the 50 µg/day treatment, suggestive of an equally efficacious dose with potentially reduced toxicity. …”
  17. 19597
  18. 19598
  19. 19599
  20. 19600